São Paulo is one of the 26 states of the Federative Republic of Brazil and is named after Saint Paul of Tarsus. A major industrial complex, the state has 21.9% of the Brazilian population and is responsible for 33.9% of Brazil's GDP.

During the past decade, UNESP - Faculdade de Medicina da Universidade Estadual Paulista - Campus Botucatu conducted 32 clinical trials. In the 10-year time frame, 32 clinical trials started and 13 clinical trials were completed, i.e. on average, 40.6% percent of trials that started reached the finish line to date. In the past 5 years, 16 clinical trials started and 12 clinical trials were completed. i.e. 75% of trials that started reached the finish line.

Out of the total clinical trials conducted in "UNESP - Faculdade de Medicina da Universidade Estadual Paulista - Campus Botucatu" #1 sponsor was "UPECLIN HC FM Botucatu Unesp" with 12 trials, followed by "Hoffmann-La Roche" with 5 trials sponsored, "Janssen Research & Development, LLC" with 5 trials sponsored, "Eli Lilly and Company" with 4 trials sponsored and "Takeda" with 4 trials sponsored. Other sponsors include 12 different institutions and companies that sponsored additional 18 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "UNESP - Faculdade de Medicina da Universidade Estadual Paulista - Campus Botucatu" #1 collaborator was "Coordenação de Aperfeiçoamento de Pessoal de Nível Superior." with 5 trials as a collaborator, "Faculdade de Medicina de Botucatu, UNESP, Botucatu, Brasil" with 4 trials as a collaborator, "Fundação de Amparo à Pesquisa do Estado de São Paulo" with 4 trials as a collaborator, "Brazilian Research In Intensive Care Network" with 2 trials as a collaborator and "Hospital Sirio-Libanes" with 2 trials as a collaborator. Other collaborators include 7 different institutions and companies that were collaborators in the rest 15 trials.

According to Clinical.Site data, the most researched conditions in "UNESP - Faculdade de Medicina da Universidade Estadual Paulista - Campus Botucatu" are "Colitis, Ulcerative" (4 trials), "Crohn Disease" (4 trials), "Crohn's Disease" (4 trials), "Juvenile Idiopathic Arthritis" (4 trials) and "COVID-19" (3 trials). Many other conditions were trialed in "UNESP - Faculdade de Medicina da Universidade Estadual Paulista - Campus Botucatu" in a lesser frequency.

Most popular intervention types in "UNESP - Faculdade de Medicina da Universidade Estadual Paulista - Campus Botucatu" are "Drug" (37 trials), "Other" (3 trials) and "Biological" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (15 trials), "Etrolizumab" (4 trials), "Baricitinib" (3 trials), "Guselkumab Dose 1" (3 trials) and "Guselkumab Dose 2" (3 trials). Other intervention names were less common.

The vast majority of trials in "UNESP - Faculdade de Medicina da Universidade Estadual Paulista - Campus Botucatu" are 42 trials for "All" genders and 4 trials for "Female" genders.

Currently, there are NaN active trials in "UNESP - Faculdade de Medicina da Universidade Estadual Paulista - Campus Botucatu". undefined are not yet recruiting, 8 are recruiting, 6 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 28 completed trials in UNESP - Faculdade de Medicina da Universidade Estadual Paulista - Campus Botucatu, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in UNESP - Faculdade de Medicina da Universidade Estadual Paulista - Campus Botucatu, 1 "Phase 1" clinical trials were conducted, 8 "Phase 2" clinical trials and 25 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 6 trials, and there were also 0 trials that are defined as “Not Applicable".

UNESP - Faculdade de Medicina da Universidade Estadual Paulista - Campus Botucatu has several departments that took part in Clinical trials: "Periodontics Clinic, Department of Dentistry" - 4 trials, "Dental Clinical Research Center of the Fluminense Federal University" - 2 trials